



Express Mail Label No. EM209742371US

PTO/SB/08a/b (01-08)

Approved for use through 01/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if known		
				Application Number	08/552,839	
Sheet		1	of	2	Examiner Name	Christopher S.F. Low
					Attorney Docket Number	105576-0044-104

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		5,173,414	12/22/1992	Lebkowski et al.	
		5,252,479	10/12/1993	Srivastava	
		5,354,678	10/11/1994	Lebkowski et al.	
		5,756,283	05/26/1998	Wilson et al.	
		2003/0096787 A1	05/22/2003	Perricaudet et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 96/14061	05/17/1996	Cell Genesys, Inc.		
		WO 96/22378	07/25/1996	Rhone-Poulenc Rorder S.A.		√ Abs
		WO 96/39530	12/12/1996	The Trustees of the University of Pennsylvania		
		CA 2 141 212	04/17/2007	Transgene S.A., FR		√ Abs
		CA 2 145 641	05/27/2008	Genzyme Corporation		
		CA 2 161 962	10/05/1999	The Regents of the University of Michigan		
		CA 2 192 442	09/25/2007	Genvec, Inc.		
		CA 2 204 357	09/11/2007	Cell Genesys, Inc.		
		EP 0 797 436	03/15/2006	Cell Genesys, Inc.		
		JP 4167725	10/22/2008	Cell Genesys, Inc.		√ Abs
		JP 7509616	10/26/1995	Transgene S.A., FR		√ Abs
		JP 8501703	02/27/1996	Rhone-Poulenc Rorder S.A.		√ Abs
		JP 11504502	04/27/1999	Rhone-Poulenc Rorder S.A.		√ Abs
		JP 11507240	06/29/1999	The Trustees of the University of Pennsylvania		√ Abs
		JP 2005-269997	10/06/2005	Kumamoto Tech & Ind. Found		√ Abs
		JP 2008-200043	09/04/2008	Cell Genesys, Inc.		√ Abs

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if known

Application Number	08/552,839
Filing Date	November 3, 1995
First Named Inventor	Qing Wang
Art Unit	1636; Confirmation No. 5915
Examiner Name	Christopher S.F. Low
Attorney Docket Number	105576-0044-104

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kathleen L. Berkner, "Development of adenovirus vectors for the expression of heterologous genes," <i>Biotechniques</i> , 6, pp. 616-629 (1989).	
		Barrie J. Carter, "Adeno-associated virus vectors," <i>Current Opinion in Biotechnology</i> , 3, pp.533-539 (1992).	
		Robert D. Gerard et al., "Adenovirus-mediated gene transfer," <i>Trends Cardiovasc Med.</i> , 3, pp. 171-177 (1993).	
		F.L. Graham et al., "Adenovirus-based expression vectors and recombinant vaccines," <i>Biotechnology</i> , Chapter 16, 363-390 (1992).	
		F.L. Graham et al., "Characteristics of a human cell line transformed by DNA from human adenovirus type 5," <i>J. Gen. Virol.</i> , 36, pp. 59-72 (1977).	
		Tim Harrison et al., "Host-range mutants of adenovirus type 5 defective for growth in HeLa cells," <i>Virology</i> , 77, pp. 319-329 (1977).	
		Michael J. Imperiale et al., "Adenovirus 5 E2 transcription unit: an E1A-inducible promoter with an essential element that functions independently of position or orientation," <i>Molecular and Cellular Biology</i> , 4, pp. 875-882 (1984).	
		N.C. Jones et al., "Trans-acting protein factors and the regulation of eukaryotic transcription: lessons from studies on DNA tumor viruses," <i>Genes Dev.</i> , 2, pp. 267-281 (1988).	
		Kwang-Soo Kim et al., "Both the basal and inducible transcription of the tyrosine hydroxylase gene are dependent upon a cAMP response element," <i>Journal of Biological chemistry</i> , 268, pp. 15689-15696 (1993).	
		Robert M. Kotin, "Prospects for the use of adeno-associated virus as a vector for human gene therapy," <i>Human Gene Therapy</i> , 5, pp. 793-801 (1994).	
		Karen F. Kozarsky et al., "Gene therapy: adenovirus vectors," <i>Current Opinion in Genetics and Development</i> , 3, pp. 499-503 (1993).	
		Kevin A. W. Lee, "Distinguishable promoter elements are involved in transcriptional activation by E1a and cyclic AMP," <i>Molecular and Cellular Biology</i> , 9, pp. 4390-4397 (1989).	
		M. Aleida Leza et al., "Independent cyclic AMP and E1A induction of adenovirus early region 4 expression," <i>Journal of Virology</i> , 63, pp. 3057-3064 (1989).	
		Karin Ohman et al., "Two adenovirus proteins with redundant activities in virus growth facilities tripartite leader mRNA accumulation," <i>Virology</i> , 194, pp. 50-58 (1993).	
		David H. Weinberg et al., "Adenoviral early region 4 is required for efficient viral DNA replication and for late gene expression," <i>Journal of Virology</i> , 57, pp. 833-838 (1986).	
		Bruce C. Trapnell, "Adenoviral vectors for gene transfer," <i>Advanced Drug Delivery Reviews</i> , 12, pp. 185-199 (1993).	
		Xiao Xiao et al, "Adeno-associated virus (AAV) vectors for gene transfer," <i>Advanced Drug Delivery Reviews</i> , 12, pp. 201-215 (1993).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.